X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Buchanan Ingersoll’s CEO and president, Bill Newlin, has long maintained that the biotechnology field is significant to the region’s economy, and he recently reiterated the firm’s commitment to serving this rapidly growing industry. With several international clients in the biotechnology and health-care fields, Buchanan has established an office to serve those clients in Dublin, Ireland. The office will open this month with Noel Daly, a well-known consultant in the health-care industry, joining the firm in Dublin. In his 31-year career, Daly has served as a consultant to the World Health Organization, was CEO of the Irish Nursing Board and managing director of Gerber Alley, a software producer. Before joining Buchanan, he was vice president of the First Consulting Group. Among other accomplishments, Newlin said, Daly has led the development of national plans to restructure health services in Zambia, Tanzania, Liberia and Kenya relating to HIV and AIDS programs. Newlin said Daly has a vast knowledge of the name players — both financiers and providers — in the European health-care market and a broad network of specialized consultants he can gather for almost any kind of project. Newlin said the Dublin office initially would be staffed around Daly, and, although the firm does not have any immediate plans for growth, he expects the new venture to mirror the growth pattern at the firm’s London office, which opened three years ago. At first, Buchanan established a health-care consultancy office in London, but the firm since has added legal services geared toward large government projects, venture capital, technology, and corporate and international insurance. Though the Philadelphia office has only recently become involved with both the health-care and biotechnology fields, with Tom Tammany, former general counsel of the University of Pennsylvania Health System heading the health-care group, Philadelphia lawyers will be working closely with the European offices to foster their joint goals. “We’ll send lawyers on an occasional basis to the Dublin office,” said Kevin Silverang, managing partner of the Philadelphia office. “We have a local initiative in both health care and intellectual property that we are trying to build in the Philadelphia office, and because of those, we will be working closely with both the Dublin and London offices.” Newlin said that Dublin’s growth would be dictated by market trends but that he expects it to involve health care, biomedicine and biotechnology, and venture capital. “As you expand into free markets, you enter a number of areas that you begin to emphasize which are the ones that make the best sense according to market trends,” Newlin said. “It’s important to keep making adjustments.” Newlin credited Buchanan’s handling of the reorganization of The Mater, Ireland’s largest Catholic-owned hospital, with establishing a solid presence in Europe. The firm began working on the reorganization two years ago, and the work continues. “The Mater is expected to be a model for other large European health-care institutions considering restructuring,” Newlin said. “This reorganization involved some groundbreaking work.” Newlin would not provide details of the reorganization. But he said the firm created the method and structure for reorganizing the entire health system. Other work in health care in Ireland includes analysis of the use of surgery and operating suites at Cork University Hospital and implementation of management changes at Laughlintown Hospital, which was the second phase of an earlier reorganization handled by the Irish government. While health care will continue to play a major role in Buchanan’s involvement in Ireland, technology and, more specifically, biotechnology in the country is another significant factor that took the firm there, Newlin said. Newlin said Ireland is the largest exporter of software. This, along with the country’s position as a center point for international expansion, was in the firm’s decision to open an office in Ireland. “Opening an office there indicates our commitment to the Irish business community and the amount of our activity within that business community,” Newlin said. “We have been doing business in Ireland for some time, and the opening is occurring in Ireland largely because it is such a technology-driven country.” Buchanan has about 40 lawyers firmwide working in biotechnology, with clients throughout the United States and the United Kingdom, as well as in Australia, Germany and Finland. Ron Schuler, co-chairman of Buchanan’s biotechnology group, said that Ireland recognizes the need for U. S. involvement in the biotech arena. That recognition opened the door for the firm, he said. “[Ireland is] trying to build a regional center in biotechnology, and the U.S. represents one-third of the market in biotechnology,” Schuler said. “They can’t do it without the U.S. and the Food and Drug Administration. Ireland needs to reach out to the U.S. “We think we can provide that type of service. We provide a gateway practice for a lot of regional centers in Europe.” Buchanan also provides expertise regarding FDA policy. Four of the firm’s partners are former administrators at the agency. And the practice group recently added former senior White House official Steven Hilton to the firm’s Washington, D.C., office. Newlin said Hilton has represented pharmaceutical companies involved in policy development on Capitol Hill and before the FDA. Buchanan’s health-care practice has grown to the point where it has represented domestic providers in 60 major mergers and acquisitions worth a combined $9 billion during the past few years. Schuler, who is based in Buchanan’s Pittsburgh office but spends considerable time each month in London, said the firm’s presence in Ireland would bolster its standing in the biotech field locally. “No one can do it alone,” he said. “People in Dublin and people in Pittsburgh will have to reach out and collaborate with people throughout the world. You need to bring in others in order to help establish Pittsburgh. Strategic alliances build more feasible companies.”

This content has been archived. It is available exclusively through our partner LexisNexis®.

To view this content, please continue to Lexis Advance®.

Not a Lexis Advance® Subscriber? Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at [email protected]

 
 

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.